Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hyphens Pharma International Ltd. ( (SG:1J5) ) has issued an announcement.
Hyphens Pharma has launched Winlevi®, a novel topical acne treatment, in Singapore and Malaysia, marking its first entry into Southeast Asia. This launch, facilitated by an exclusive agreement with Cassiopea S.p.A., represents a strategic expansion in the dermatology space, with plans to introduce the product in other Southeast Asian markets. Winlevi® is notable for its unique mechanism targeting the androgen-sebum pathway, offering a safe treatment option for acne without systemic side effects.
The most recent analyst rating on (SG:1J5) stock is a Buy with a S$0.40 price target. To see the full list of analyst forecasts on Hyphens Pharma International Ltd. stock, see the SG:1J5 Stock Forecast page.
More about Hyphens Pharma International Ltd.
Hyphens Pharma International Ltd. is Singapore’s leading specialty pharmaceutical and consumer healthcare group, focusing on expanding its presence in the dermatology sector.
Average Trading Volume: 75,076
Technical Sentiment Signal: Buy
Current Market Cap: S$100.5M
See more insights into 1J5 stock on TipRanks’ Stock Analysis page.